Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

Trial ID or NCT#

NCT02768558

Status

not recruiting iconNOT RECRUITING

Purpose

Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.

Official Title

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Billy W Loo
Billy W Loo
Radiation oncologist, Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy)
Maximilian Diehn
Maximilian Diehn
Radiation oncologist
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov